Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1991 Dec;21(6):418-30.
doi: 10.2165/00003088-199121060-00003.

Felodipine clinical pharmacokinetics

Affiliations
Review

Felodipine clinical pharmacokinetics

P H Dunselman et al. Clin Pharmacokinet. 1991 Dec.

Abstract

Absorption of felodipine is rapid and complete. A pronounced first-pass metabolism results in a bioavailability of 15%, irrespective of the oral formulation used. The peak plasma concentrations and area under the plasma concentration-time curve are linearly related to the dose. The variability in plasma concentrations is wide, and individualization of the dosage is recommended. Plasma felodipine concentrations are increased in the elderly, and in patients with congestive heart failure or liver cirrhosis; in these patients felodipine should be started at a low dosage. Food intake has no clinically significant effect on felodipine absorption. Serum digoxin concentrations are increased by felodipine in plain tablet form, but not when it is administered as extended release tablets. Activators, inducers and inhibitors of the cytochrome P450 system affect the plasma concentrations of felodipine. No displacement reactions with high affinity protein binding drugs have been observed. There is a significant correlation between plasma concentration and haemodynamic effect. The mean elimination half-life of 24h together with the extended release formulation of felodipine favours once-daily dosage in patients with hypertension.

PubMed Disclaimer

References

    1. Eur J Clin Pharmacol. 1983;24(1):49-53 - PubMed
    1. Br Heart J. 1984 Oct;52(4):431-4 - PubMed
    1. Drugs. 1985;29 Suppl 2:87 - PubMed
    1. J Cardiovasc Pharmacol. 1989 Sep;14(3):438-43 - PubMed
    1. Clin Pharmacol Ther. 1985 Aug;38(2):205-11 - PubMed

LinkOut - more resources